Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Neoplasma"
DOI: 10.4149/neo_2018_171019n668
Abstract: Natural killer (NK) cell-based immunotherapy is promising, as NK cells are in the first line of defense against cancer and capital of lysing tumor cells without pre-stimulation. However, NK cells from multiple myeloma (MM) patients… read more here.
Keywords: patient autologous; natural killer; vivo expanded; cell ... See more keywords